{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.917","upperLimit":"3","value":"1.53"},{"groupId":"OG002","lowerLimit":"0.917","upperLimit":"2.62","value":"1.55"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"Cycle 1, NSCLC patients"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.45","upperLimit":"2","value":"1.55"},{"groupId":"OG002","lowerLimit":"1.5","upperLimit":"2.33","value":"1.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"title":"Cycle 3, NSCLC patients"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.43","upperLimit":"3","value":"1.51"},{"groupId":"OG002","lowerLimit":"1.07","upperLimit":"2.9","value":"1.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"21"}],"units":"Participants"}],"title":"Cycle 1, melanoma patients"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.45","upperLimit":"2","value":"1.53"},{"groupId":"OG002","lowerLimit":"0.683","upperLimit":"1.82","value":"1.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"title":"Cycle 3, melanoma patients"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"3","value":"1.51"},{"groupId":"OG002","lowerLimit":"1","upperLimit":"2.05","value":"1.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"Cycle 1, RCC patients"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.48","upperLimit":"2.08","value":"1.58"},{"groupId":"OG002","lowerLimit":"1.45","upperLimit":"2.8","value":"1.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"title":"Cycle 3, RCC patients"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.583","upperLimit":"3","value":"1.53"},{"groupId":"OG002","lowerLimit":"1.47","upperLimit":"2.08","value":"1.55"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"title":"Cycle 1, mesothelioma patients"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.967","upperLimit":"2.13","value":"1.5"},{"groupId":"OG002","lowerLimit":"1.42","upperLimit":"2.08","value":"1.52"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"title":"Cycle 3, mesothelioma patients"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.567","upperLimit":"3","value":"1.53"},{"groupId":"OG001","lowerLimit":"1.43","upperLimit":"3","value":"1.53"},{"groupId":"OG002","lowerLimit":"0.95","upperLimit":"2","value":"1.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"13"}],"units":"Participants"}],"title":"Cycle 1, TNBC patients"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.48","upperLimit":"2","value":"1.63"},{"groupId":"OG001","lowerLimit":"1.7","upperLimit":"1.92","value":"1.78"},{"groupId":"OG002","lowerLimit":"1","upperLimit":"2","value":"1.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"Cycle 3, TNBC patients"}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"92"}],"units":"Participants"}],"description":"Pharmacokinetic (PK) parameters were calculated based on LAG525 serum concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) serum concentration following a dose. Actual recorded sampling times were considered for the calculations.","dispersionType":"Full Range","groups":[{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients naïve to anti-PD-1/PD-L1","id":"OG000","title":"Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 600 mg + PDR001 400 mg (Q4W/Q4W) in patients naïve to anti-PD-1/PD-L1","id":"OG001","title":"Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients pre-treated with anti-PD-1/PD-L1","id":"OG002","title":"Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W"}],"paramType":"MEDIAN","populationDescription":"All patients in phase 2 who received at least one full or partial dose of LAG525 and who had at least one serum sample providing evaluable PK data.","reportingStatus":"POSTED","timeFrame":"pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).","title":"Phase 2: Time to Reach Maximum Serum Concentration (Tmax) of LAG525","type":"SECONDARY","unitOfMeasure":"days"}